Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 21 June 2024, including: the outlook for 2025 launches; Merck & Co., Inc. confident in new pneumococcal vaccine; multiple US setbacks for Japanese firms; Stock Watch on Moderna, Inc. missteps; and Sun Pharmaceutical Industries Ltd.’s North America head talks plans and strategy.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Cagrisema Leads The Charge For 2025" - Scrip, 19 June, 2024.)
(Also see "Merck’s Newly Approved Capvaxive Could Have Edge Over Prevnar 20 In Adults" - Scrip, 18 June, 2024.)
(Also see "US R&D Setbacks For Multiple Japanese Firms" - Scrip, 14 June, 2024.)
(Also see "Stock Watch: Thoroughly Moderna Missteps" - Scrip, 18 June, 2024.)
(Also see "Sun’s Gandhi On US Specialty Journey Sans ‘Baggage’, Deuruxolitinib" - Scrip, 17 June, 2024.)
